Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

Results Follow ACTIVATE Study Data In December

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.

3-D Rendering Red Blood Cells
Agios' trial of mitapivat shows reduction in transfusion burden among patinets with rare anemia. • Source: Shutterstock

More from Business

More from Scrip